Home > Search Results: Voest, Emile
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
5 p, 332.1 KB Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers / Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Vyas, Malvika (European Society for Medical Oncology) ; Giuliani, Rosa (San Camillo Forlanini Hospital) ; Arnold, Dirk (CUF Hospitals) ; Cardoso, Fatima (Champalimaud Clinical Center) ; Casali, Paolo Giovanni (Fondazione IRCCS National Cancer Institute) ; Cervantes, Andrés (Clinic Hospital) ; Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ; Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ; Jassem, Jacek (Medical University of Gdansk) ; Pentheroudakis, George (University of Ioannina) ; Peters, Solange (Centre Hospitalier Universitaire Vaudois) ; Rauh, Stefan (Hospital Center Emile Mayrisch) ; Zielinski, Christoph C. (Medical University of Vienna) ; Stahel, Rolf A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Voest, Emile (University Hospital Zurich (Suïssa)) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; McGregor, Keith (European Society for Medical Oncology) ; Ciardiello, Fortunato (Second University of Naples) ; Universitat Autònoma de Barcelona
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. [...]
2017 - 10.1136/esmoopen-2016-000142
ESMO open, Vol. 1 (january 2017)  
Detailed record - Creative Commons
2.
9 p, 1.8 MB Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours / Fernandes Neto, João M. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Nadal, Ernest (Institut d'Investigació Biomèdica de Bellvitge) ; Bosdriesz, Evert (Vrije Universiteit) ; Ooft, Salo N. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Farre, Lourdes (Fundação Oswaldo Cruz (Brasil)) ; McLean, Chelsea (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Klarenbeek, Sjoerd (The Netherlands Cancer Institute. Experimental Animal Pathology) ; Jurgens, Anouk (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Hagen, Hannes (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Wang, Liqin (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Felip, Enriqueta (Universitat Autònoma de Barcelona) ; Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ; Vidal, August (Institut d'Investigació Biomèdica de Bellvitge) ; Voest, Emile (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Wessels, Lodewyk F. A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; van Tellingen, Olaf (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Villanueva, Alberto (Hospital Universitari de Bellvitge) ; Bernards, Rene (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. [...]
2020 - 10.1038/s41467-020-16952-9
Nature communications, Vol. 11 (june 2020)  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with